Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab + lenvatinib neoadjuvant therapy in high-risk localized and locally advanced renal cell carcinoma
ChiCTR2500108135Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab, tuvonralimab and lenvatinib in clear cell renal cell carcinoma (ccRCC), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Objective response rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimablenvatinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2500108135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108135.